Chimerix, Inc.

NasdaqGM:CMRX Rapport sur les actions

Capitalisation boursière : US$801.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Chimerix Gestion

Gestion contrôle des critères 2/4

Le PDG Chimerix est Mike Andriole, nommé en Aug2023, a un mandat de 1.67 ans. La rémunération annuelle totale est $ 1.46M, composée du salaire de 41.5% et des bonus 58.5%, y compris les actions et options de la société. détient directement 0.39% des actions de la société, d'une valeur de $ 3.09M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.7 ans et 6 ans.

Informations clés

Mike Andriole

Directeur général

US$1.5m

Rémunération totale

Pourcentage du salaire du PDG41.48%
Durée du mandat du directeur général1.7yrs
Propriété du PDG0.4%
Durée moyenne d'occupation des postes de direction1.7yrs
Durée moyenne du mandat des membres du conseil d'administration6yrs

Mises à jour récentes de la gestion

Recent updates

Seeking Alpha • Feb 20

Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients

Summary The company holds the potential to have the first approval of dordaviprone for the treatment of recurrent H3 K27M mutant high-grade glioma patients; PDUFA with a Priority Review date of August 18th, 2025. The global brain tumor therapeutics market is expected to grow to $5.28 billion by 2030; the Company notes that it could obtain >$1 billion in revenues in the United States alone. Phase 3 ACTION study using dordaviprone for the treatment of front-line H3 K27M mutant high-grade glioma patients to have OS interim data readout in Q3 of 2025. FDA approval of dordaviprone for the treatment of patients with recurrent H3 K27M mutant high-grade glioma could allow the company to receive a Priority Review Voucher, which it could keep or sell. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Summary Chimerix, Inc.'s dordaviprone shows promise in treating H3 K27M-positive glioma, with a potential FDA approval and commercial launch by Q3 2025. CMRX's strong clinical data and high unmet need in diffuse midline glioma bolster confidence in FDA approval, despite potential timeline uncertainties. Financially, CMRX has a cash runway of 6–7 quarters, sufficient to reach an FDA decision, but risks of dilution remain. Given the recent market surge and promising outlook, I maintain a favorable rating on CMRX stock, anticipating significant market capitalization growth. Read the full article on Seeking Alpha
Article d’analyse • Jul 16

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Aug 23

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Initiation of phase 3 ACTION study using ONC201 for treatment of glioma patients who harbor the H3 K27M mutation is expected in the 2nd half of 2022. Interim results from the ACTION study are expected in early 2025, with final results expected in 2026. Proof of concept data using ONC201 has already been established in two phase 2 studies; in patients with H3 K27M mutation gliomas and neuroendocrine tumors. Additional imipridones being developed in the pipeline are ONC206 and ONC212 for oncology indications; CMX521 being advanced as prophylactic and treatment for Covid-19. Chimerix, Inc. (CMRX) is a great speculative biotech that should be on your radar. While it is still a risky longer-term play, I believe it could have value based on established proof of concept using ONC201 for the treatment of patients with H3 K27M-mutant glioma. In a phase 2 study, it showed to improve overall survival rates in this specific population, which I will show below. The only downside is that the first interim analysis is not expected until early 2025 with final data not coming out until 2026. However, ONC201 is also being explored in a phase 2 study in neuroendocrine tumors. Such neuroendocrine tumors being explored are Pheochromocytoma/paraganglioma. Initial data was revealed which established some proof of concept of the mechanism of action. Even then, it is working on a second generation imipridone known as ONC206 which is much improved compared to 1st generation ONC201. It is believed that ONC206 provides greater anti-tumor activity compared to ONC201 and thus it is also being advanced in the pipeline. The biotech also entered into an agreement with Emergent BioSolutions ((EBS)) for the sale of worldwide rights to TEMBEXA for a $225 million upfront payment, potential milestone payments and double-digit royalties on net sales as well. It is important to note that this agreement is still in the process of being completed. This agreement relies on additional items being executed. If the agreement goes through with EBS, then the biotech will have enough cash into 2027. Lastly, it is in the process of developing an improved oral formulation of CMX521 as a prophylactic and treatment of SARS-CoV-2 (Covid-19) in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative ((READDI)). While early in the process and already many approved treatments in this space, I believe it could still act as a catalyst if it is successfully advanced. It is believed that animal data will be released in the 2nd half of 2022 on such an improved oral formulation for CMX521 for Covid-19. With a growing pipeline, plus some established proof of concept of ONC201 in a rare brain glioma and neuroendocrine tumors, I believe it is a great speculative biotech play to look into. Imipridone ONC201 Could Possibly Greatly Improve Overall Survival Rates For Rare Gliomas The main drug in Chimerix's pipeline would be ONC201, which is being developed for the treatment of patients with gliomas who harbor the H3 K27M mutation. What occurs with respect to this specific type of glioma? What occurs is the H3K27M mutation itself puts in a new amino acid known as H3, which promotes a gene expression that enable tumor growth to occur. Patients with this type of glioma have poor prognosis and definitely need new types of treatments to be approved. Before diving into ONC201 clinical results, it's important to understand what the drug actually is. Again, it is an imipridone which targets G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease p (ClpP), resulting in cancer death. Cell death happens with the induction of the integrated stress response and upregulation pathway of apoptotic (cell death) factors, such as tumor necrosis factor ((TNF)) related apoptosis-inducing ligand ((TRAIL)). More specifically, it selectively induces cell death by binding and altering activity of DRD2 (Selectively coupled G-protein receptor) and ClpP. This is further established with the following action: DRD2 antagonism is responsible for inhibiting Ras signaling pathway that cancer has ClpP degrades excess amount of mitochondrial proteins which are important for the cancer cell to be viable Remember above when I stated that H3 K27M mutation uses amino acid H3 to promote gene expression for the cancer? Well, ONC201 was established to alter this gene expression making it sensitive to the drug itself. All these actions are what are put in place to specifically treat glioma patients who harbor the H3 K27M mutation. Moving onto the program advancement at hand, the company intends to initiate a phase 3 study in the 2nd half of 2022 known as ACTION. This is going to be a randomized late-stage study using ONC201 for the treatment of newly diagnosed diffuse glioma patients whose tumors harbor the H3 K27M mutation. It is expected that about 450 patients will be randomized 1:1:1 to receive doses as followed: 625 mg ONC201 once per week 625 mg ONC201 twice per week Placebo The primary endpoint of this study is overall survival ((OS)). Patients will first be treated with radiation and then be randomized to one of the dosing groups noted directly above. As far as catalysts go for this study, it could be quite some time to see data. It is said that the first interim analysis for results is not expected until 2025. From there, final data from this ACTION study is not expected until 2026. The thing is that it may be a good market to tap into despite the fact how rare the H3 K27M mutation glioma is. Chimerix believes it can earn above $500 million in sales annually should it ultimately get ONC201 to market for this specific population. Despite results taking time to come out, it's important to note that there is a great shot at clinical success. That's because ONC201 monotherapy was able to achieve an overall response rate ((ORR)) of 30% by RANO HGG and/or LGG by dual reader BICR. Even better, is what those treated with this drug obtained in terms of overall survival rates. For the H3 K27M recurrent glioma patients given ONC201, overall survival at 12 months and 24 months was 57% and 35%, respectively, whereas historical control at 12 months and 24 months was 27.5% and 6.4%, respectively. What does this show? This shows that with the biotech specifically targeting patients with this H3 K27M mutation by using ONC201, it can improve overall survival for them. Proof Of Concept For ONC201 In Treatment Of Patients With Neuroendocrine Tumors In addition to some proof of concept being established in a phase 2 study with ONC201 in patients with H3 K27M mutated gliomas, the drug had also seen some mechanism of action in patients with neuroendocrine tumors. One neuroendocrine tumor being explored is paraganglioma. A paraganglioma is a type of neuroendocrine tumor that forms near certain blood vessels and nerves outside of the adrenal glands. The adrenal glands being affects is not a very good thing, considering they are responsible for making hormones which control many functions in the body. In an open-label phase 2 investigator-initiated study with 30 patients, treatment with ONC201 performed pretty well. The cohort of paraganglioma patients who were dosed with ONC201 once a week performed better than the other cohort of patients dosed twice a week with ONC201. For these patients who were dosed once weekly with ONC201, the outcome was as follows: 5 out of 10 patients (50%) achieved a partial response ((PR)) 2 out of 10 patients achieved stable disease ((SD)) The other neuroendocrine tumor also being evaluated with the use of this drug is Pheochromocytoma, which is a hormone secreting tumor that can occur in the adrenal glands. Additional Shots On Goal With Imipridones ONC206 And ONC212
Article d’analyse • Jul 20

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 06

Chimerix: Down But Not Out

Today, we revisit an interesting small-cap concern called Chimerix that trades for around two bucks a share, and under cash value. The company recently announced a deal to sell off its one approved drug for over $200 million, which was received negatively by the market. Chimerix will now pivot fully to developing the other parts of its pipeline. We revisit the investment case around Chimerix in the paragraphs below.
Seeking Alpha • Jan 05

Chimerix: Searching For Clarity

Today, we put Chimerix, Inc. in the spotlight for the first time. The company recently received an FDA approval and has several other promising compounds in development. A full investment analysis is provided in the paragraphs below.
Article d’analyse • Dec 24

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Article d’analyse • Sep 16

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Article d’analyse • Jun 08

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Article d’analyse • May 13

Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

With the business potentially at an important milestone, we thought we'd take a closer look at Chimerix, Inc.'s...

Analyse de la rémunération des PDG

Comment la rémunération de Mike Andriole a-t-elle évolué par rapport aux bénéfices de Chimerix?
DateRémunération totaleSalaireBénéfices de l'entreprise
Dec 31 2024US$1mUS$608k

-US$88m

Sep 30 2024n/an/a

-US$84m

Jun 30 2024n/an/a

-US$85m

Mar 31 2024n/an/a

-US$83m

Dec 31 2023US$1mUS$528k

-US$82m

Sep 30 2023n/an/a

-US$85m

Jun 30 2023n/an/a

US$180m

Mar 31 2023n/an/a

US$176m

Dec 31 2022US$2mUS$455k

US$172m

Sep 30 2022n/an/a

US$154m

Jun 30 2022n/an/a

-US$106m

Mar 31 2022n/an/a

-US$101m

Dec 31 2021US$2mUS$433k

-US$173m

Sep 30 2021n/an/a

-US$145m

Jun 30 2021n/an/a

-US$138m

Mar 31 2021n/an/a

-US$131m

Dec 31 2020US$960kUS$420k

-US$44m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$98m

Mar 31 2020n/an/a

-US$105m

Dec 31 2019US$1mUS$292k

-US$113m

Rémunération vs marché: La rémunération totale de Mike ($USD 1.46M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 3.73M ).

Rémunération et revenus: La rémunération de Mike a augmenté alors que l'entreprise n'est pas rentable.

PDG

Mike Andriole (51 yo)

1.7yrs
Titularisation
US$1,464,678
Compensation

Mr. Michael T. Andriole, also known as Mike, MBA, is CEO, President & Director of Chimerix, Inc. since August 01, 2023 and had been the Chief Business Officer of Chimerix, Inc. since April 8, 2019 until Au...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Michael Andriole
CEO, President & Director1.7yrsUS$1.46m0.39%
$ 3.1m
Michael Alrutz
Senior VP10.6yrsUS$800.29k0.15%
$ 1.2m
Allen Melemed
Chief Medical Officer4.8yrsUS$919.54k0.078%
$ 623.3k
Michelle LaSpaluto
Chief Financial Officer1.3yrspas de données0.18%
$ 1.5m
Thomas Riga
Chief Operating & Commercial Officer1.4yrspas de données0.061%
$ 491.1k
David Jakeman
Vice President of Accounting & Finance5.8yrspas de données0.13%
$ 1.0m
Roy Ware
Chief Manufacturing & Technology Officerno datapas de donnéespas de données
Joshua Allen
Chief Scientific Officerless than a yearpas de donnéespas de données
1.7yrs
Durée moyenne de l'emploi
50yo
Âge moyen

Gestion expérimentée: L'équipe de direction de CMRX n'est pas considérée comme expérimentée (ancienneté moyenne 1.7 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Michael Andriole
CEO, President & Director1.7yrsUS$1.46m0.39%
$ 3.1m
Fred Middleton
Independent Director7.1yrsUS$99.07k0.33%
$ 2.6m
Seth Rudnick
Member of Scientific Advisory Boardno datapas de donnéespas de données
Martha Demski
Lead Independent Director20.3yrsUS$124.07k0.077%
$ 615.3k
Michael Sherman
Chairman6yrsUS$114.07k0.38%
$ 3.0m
Marc Kozin
Independent Director1.1yrsUS$153.36kpas de données
Douglas Richman
Member of Scientific Advisory Boardno datapas de donnéespas de données
Michael Boeckh
Member of Clinical Advisory Boardno datapas de donnéespas de données
Earl Kern
Member of Scientific Advisory Boardno datapas de donnéespas de données
Raymund Razonable
Member of Clinical Advisory Boardno datapas de donnéespas de données
Robert Meyer
Independent Director7.1yrsUS$97.94k0.037%
$ 300.2k
Victoria Vakiener
Independent Director4yrsUS$92.08k0%
$ 0
6.0yrs
Durée moyenne de l'emploi
64yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de CMRX sont considérés comme expérimentés (ancienneté moyenne 6 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2025/04/22 04:54
Cours de l'action en fin de journée2025/04/17 00:00
Les revenus2024/12/31
Revenus annuels2024/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Chimerix, Inc. est couverte par 15 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Geoffrey MeachamBarclays
Debjit ChattopadhyayBrean Capital Historical (Janney Montgomery)
Ritu BaralCanaccord Genuity